The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Indian pharma company Natco Pharma Ltd over entecavir, a pharmaceutical combination for treating Hepatitis B has been settled amicably, both the companies informed Intellectual Property Appellate Board (IPAB). While the terms of settlement were incorporated in the miscellaneous petition, which sought the IPAB to withdraw the rectification application, the parties requested the court that the registry should not allow any third party to see the terms of settlement. According to information available the rectification application was filed to revoke a patent of entecavir, owned by BMS. The patent, filed on July 2, 2002 was published on January 25, 2008. According to earlier reports, a US Court has invalidated a patent of the drug, marketed as Baraclude, as obvious and an appeal by BMS was denied by the US Court of Appeals for the Federal Circuit, last year. The US patent 5,206,244 was challenged by Isreal-based generics majorTeva Pharmaceutical Industries. In 2014, BMS said that it is reviewing the decision of the Court of Appeals and considering legal options.